Results 71 to 80 of about 686,182 (220)

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms

The Journal of Dermatology, EarlyView.
ABSTRACT γδ T cells represent an increasingly important subset of T lymphocytes in the immune response to cancer and as a platform for novel immunotherapies. The aim of this review is to synthesize recent insights into the biology and advances in therapeutic applications of γδ T cells in cutaneous malignancies, especially melanoma, within a framework ...
Simo Du, Anika Jallorina, Toru Yoshino, Lingyu Bao, Han Bao, Victor Chang, Henry K. Wong, Derek V. Chan, Stephen K. Richardson, Mary F. Lee‐Wong   +9 more
wiley   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Primary bone ALK-positive anaplastic large cell lymphoma presented as a giant extraskeletal mass with coagulation necrosis

Radiology Case Reports
Anaplastic large cell lymphoma (ALCL) represents one of the rare types of non-Hodgkin lymphoma. We describe a case of primary bone anaplastic lymphoma kinase (ALK)-positive ALCL presented as a giant extraskeletal mass with extensive coagulation necrosis.
Shuji Nagata, Miyuki Sawano, Yuki Shouji, Masayuki Oka, Seiji Kurata, Koji Hiraoka, Jun Akiba, Shuichi Tanoue   +7 more
doaj   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

Cancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda, Kazuo Hasegawa, Takayuki Takahama, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Masashi Yoshida, Miyuki Sakai, Sachiko Watanabe, Kazuhiko Nakagawa   +9 more
wiley   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

ALK-positive anaplastic large cell lymphoma presenting as intradural spinal mass: First reported case and review of literature

, 2013
Anaplastic large cell lymphoma (ALCL) is characterized by large anaplastic cells of T-cell or null-cell phenotype expressing CD30 (Ki-1 antigen). In most cases this neoplasm expresses the anaplastic lymphoma kinase (ALK), a chimeric protein resulting ...
Mariangela Novello, Visocchi, Massimiliano, Lauriola, Libero, Coli, Antonella, La Rocca, Giuseppe, Giuseppe La Rocca, Della Pepa, Giuseppe Maria, Antonella Coli, Novello, Mariangela, Libero Lauriola, Giuseppe Maria Della Pepa, Massimiliano Visocchi   +11 more
core   +1 more source

Discovery and efficacy study of an ALK inhibitor AMX6001 in anaplastic large cell lymphoma Karpas299 mice models

European Journal of Medicinal Chemistry Reports
Anaplastic lymphoma kinase (ALK) is an attractive therapeutic target for the treatment of anaplastic large cell lymphoma (ALCL). We identified novel deuterated 2,4-diarylamino pyrimidine compounds as potent ALK inhibitors. The compound 9 (AMX6001) showed
Debasis Das, Lingzhi Xie, Dandan Qiao, Yuxi Cao, Jianhe Jia, Yong Li, Jian Hong   +6 more
doaj   +1 more source

A rare case of paediatric non-Hodgkin's lymphoma

Journal of Clinical and Scientific Research, 2019
Anaplastic large cell lymphoma (ALCL) is a rare disease accounting for 10%–15% of all non-Hodgkin's lymphomas in children. It is distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen.
D Bhargavi, T Kannan, K L Priyadarshini, V Santhosh, K M Ramprahlad, B Sreekanth   +5 more
doaj   +1 more source

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN

Cancer Science, EarlyView.
In prespecified exploratory analyses of Japanese patients with resectable NSCLC enrolled in the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy demonstrated clinically meaningful improvements in the primary endpoints of EFS and pCR versus neoadjuvant chemotherapy alone.
Tetsuya Mitsudomi, John V. Heymach, Yoshitsugu Horio, Fumihiro Tanaka, Hiroshi Tanaka, Shoichi Kuyama, Morihito Okada, Shinichi Toyooka, Yasutaka Watanabe, Martin Reck, David Harpole, Janis M. Taube, Yuka Olivo, Huiling Xiong, Tamer M. Fouad, Allen Chen, Hiroaki Akamatsu   +16 more
wiley   +1 more source